ArticleAntimicrobial agents and chemotherapy2016
Molecular Epidemiology and Genome Dynamics of New Delhi Metallo-β-Lactamase-Producing Extraintestinal Pathogenic Escherichia coli Strains from India.
Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Global Extraintestinal Pathogenic Escherichia coli (ExPEC) Lineages.Clinical microbiology reviews · 2019Pooled it
- Molecular characterization & risk factors associated with carbapenemase-producing enterobacterales acquisition in hospitalised patients in a tertiary care setting.The Indian journal of medical research · 2025Article
- High-risk clonal groups of avian pathogenicVirulence · 2025Article
- A Decade-Long Evaluation of Neonatal Septicaemic Escherichia coli: Clonal Lineages, Genomes, and New Delhi Metallo-Beta-Lactamase Variants.Microbiology spectrum · 2023Article
- Uropathogenic Escherichia coli endeavors: an insight into the characteristic features, resistance mechanism, and treatment choice.Archives of microbiology · 2023Review
- NDM-beta-lactamase-1: Where do we stand?The Indian journal of medical research · 2022Review
- Molecular Characterization of Carbapenem-ResistantInfection and drug resistance · 2022Review
- Occurrence of New Delhi Metallo-Beta-Lactamase 1 ProducingMicrobiology insights · 2022Article
- Detection of NDM Variants (Infection and drug resistance · 2022Article
- Association Between Types of Carbapenemase and Clinical Outcomes of Infection Due to Carbapenem Resistance Enterobacterales.Infection and drug resistance · 2022Article
- Genome Dynamics and Evolution of Multiple-Drug-Resistant Bacteria: Implications for Global Infection Control Priorities.The Journal of infectious diseases · 2021Article
- Genomic Epidemiology and Antimicrobial Resistance Mechanisms of Imported Typhoid in Australia.Antimicrobial agents and chemotherapy · 2021Article
- Identification of CTX-M Type ESBLPathogens (Basel, Switzerland) · 2021Article
- Phylogenetic diversity and mutational analysis of New Delhi Metallo-β-lactamase (NDM) producingSaudi journal of biological sciences · 2021Article
- Virulence characterization and clonal analysis of uropathogenic Escherichia coli metallo-beta-lactamase-producing isolates.Annals of clinical microbiology and antimicrobials · 2021Article
- Prevalence and Antibiotic Resistance Characteristics of Extraintestinal PathogenicAnimals : an open access journal from MDPI · 2021Article
- Article
- The Potential Use of Ceftazidime-Avibactam Against Carbapenem ResistantDrug design, development and therapy · 2021Article
- High Prevalence ofAntibiotics (Basel, Switzerland) · 2020Article
- Virulence Potential of a Multidrug-ResistantMicroorganisms · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global dissemination and increasing incidence of carbapenem-resistant, Gram-negative organisms have resulted in acute public health concerns. Here, we present a retrospective multicenter study on molecular characterization of metallo-β-lactamase (MBL)-producing clinical Escherichia coli isolates recovered from extraintestinal infections in two hospitals in Pune, India. We screened a large sample size of 510 E. coli isolates for MBL production wherein we profiled their molecular determinants, antimicrobial resistance phenotypes, functional virulence properties, genomic features, and transmission dynamics. Approximately 8% of these isolates were MBL producers, the majority of which were of the NDM-1 (69%) type, followed by NDM-5 (19%), NDM-4 (5.5%), and NDM-7 (5.5%). MBL producers were resistant to all antibiotics tested except for colistin, fosfomycin, and chloramphenicol, which were effective to various extents. Plasmids were found to be an effective means of dissemination of NDM genes and other resistance traits. All MBL producers adhered to and invaded bladder epithelial (T24) cells and demonstrated significant serum resistance. Genomic analysis of MBL-producing E. coli isolates revealed higher resistance but a moderate virulence gene repertoire. A subset of NDM-1-positive E. coli isolates was identified as dominant sequence type 101 (ST101) while two strains belonging to ST167 and ST405 harbored NDM-5. A majority of MBL-producing E. coli strains revealed unique genotypes, suggesting that they were clonally unrelated. Overall, the coexistence of virulence and carbapenem resistance in clinical E. coli isolates is of serious concern. Moreover, the emergence of NDM-1 among the globally dominant E. coli ST101 isolates warrants stringent surveillance and control measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.